114
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Application Value of Serum Metabolic Markers for Cognitive Prediction in Elderly Epilepsy

, , , , &
Pages 2133-2140 | Received 03 May 2022, Accepted 03 Sep 2022, Published online: 22 Sep 2022

References

  • Annegers JF, Dubinsky S, Coan SP et al. The incidence of epilepsy and unprovoked seizures in multiethnic, urban health maintenance organizations. Epilepsia 1999; 40: 502–506. doi:10.1111/j.1528-1157.1999.tb00748.x
  • Hussain SA, Haut SR, Lipton RB, et al. Incidence of epilepsy in a racially diverse, community-dwelling, elderly cohort: results from the Einstein aging study. Epilepsy Res. 2006;71:195–205. doi:10.1016/j.eplepsyres.2006.06.018
  • Hermann BP, Dabbs K, Becker T, et al. Brain development in children with new onset epilepsy: a prospective controlled cohort investigation. Epilepsia. 2010;51:2038–2046. doi:10.1111/j.1528-1167.2010.02563.x
  • Keezer MR, Sisodiya SM, Sander JW. Comorbidities of epilepsy: current concepts and future perspectives. Lancet Neurol. 2016;15:106–115. doi:10.1016/S1474-4422(15)00225-2
  • Ravizza T, Onat FY, Brooks-Kayal AR, et al. WONOEP appraisal: biomarkers of epilepsy-associated comorbidities. Epilepsia. 2017;58:331–342. doi:10.1111/epi.13652
  • Sen A, Capelli V, Husain M. Cognition and dementia in older patients with epilepsy. Brain. 2018;141:1592–1608. doi:10.1093/brain/awy022
  • Sen A, Jette N, Husain M, et al. Epilepsy in older people. Lancet. 2020;395:735–748. doi:10.1016/S0140-6736(19)33064-8
  • Witt JA, Werhahn KJ, Kramer G, et al. Cognitive-behavioral screening in elderly patients with new-onset epilepsy before treatment. Acta Neurol Scand. 2014;130:172–177. doi:10.1111/ane.12260
  • Breteler MM, de Groot RR, van Romunde LK, et al. Risk of dementia in patients with Parkinson’s disease, epilepsy, and severe head trauma: a register-based follow-up study. Am J Epidemiol. 1995;142:1300–1305. doi:10.1093/oxfordjournals.aje.a117597
  • Sen A, Thom M, Nikolic M et al. The potential role of cyclin-dependent kinase 5 in focal cortical dysplasia. Dev Neurosci 2008; 30: 96–104. doi:10.1159/000109855
  • Scharfman HE. Alzheimer’s disease and epilepsy: insight from animal models. Future Neurol. 2012;7:177–192. doi:10.2217/fnl.12.8
  • Shi JQ, Wang BR, Tian YY, et al. Antiepileptics topiramate and levetiracetam alleviate behavioral deficits and reduce neuropathology in APPswe/PS1dE9 transgenic mice. CNS Neurosci Ther. 2013;19:871–881. doi:10.1111/cns.12144
  • Vezzani A, French J, Bartfai T, et al. The role of inflammation in epilepsy. Nat Rev Neurol. 2011;7:31–40. doi:10.1038/nrneurol.2010.178
  • Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron. 1988;1:623–634. doi:10.1016/0896-6273(88)90162-6
  • Alapirtti T, Waris M, Fallah M, et al. C-reactive protein and seizures in focal epilepsy: a video-electroencephalographic study. Epilepsia. 2012;53:790–796. doi:10.1111/j.1528-1167.2012.03449.x
  • Hermann BP, Sager MA, Koscik RL, et al. Vascular, inflammatory, and metabolic factors associated with cognition in aging persons with chronic epilepsy. Epilepsia. 2017;58:e152–e156. doi:10.1111/epi.13891
  • Mintzer S. Metabolic consequences of antiepileptic drugs. Curr Opin Neurol. 2010;23:164–169. doi:10.1097/WCO.0b013e32833735e7
  • Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci. 2004;5:553–564. doi:10.1038/nrn1430
  • Pitkanen A, Sutula TP. Is epilepsy a progressive disorder? Prospects for new therapeutic approaches in temporal-lobe epilepsy. Lancet Neurol. 2002;1:173–181. doi:10.1016/s1474-4422(02)00073-x
  • Hermann B, Seidenberg M, Sager M, et al. Growing old with epilepsy: the neglected issue of cognitive and brain health in aging and elder persons with chronic epilepsy. Epilepsia. 2008;49:731–740. doi:10.1111/j.1528-1167.2007.01435.x
  • Norton S, Matthews FE, Barnes DE, et al. Potential for primary prevention of Alzheimer’s disease: an analysis of population-based data. Lancet Neurol. 2014;13:788–794. doi:10.1016/S1474-4422(14)70136-X
  • Yuen AW, Bell GS, Peacock JL, et al. Effects of AEDs on biomarkers in people with epilepsy: CRP, HbA1c and eGFR. Epilepsy Res. 2010;91:187–192. doi:10.1016/j.eplepsyres.2010.07.011
  • Pylvanen V, Pakarinen A, Knip M, et al. Insulin-related metabolic changes during treatment with valproate in patients with epilepsy. Epilepsy Behav. 2006;8:643–648. doi:10.1016/j.yebeh.2006.02.008
  • Lopinto-Khoury C, Mintzer S. Antiepileptic drugs and markers of vascular risk. Curr Treat Options Neurol. 2010;12:300–308. doi:10.1007/s11940-010-0080-y
  • Eiris JM, Lojo S, Del Rio MC, et al. Effects of long-term treatment with antiepileptic drugs on serum lipid levels in children with epilepsy. Neurology. 1995;45:1155–1157. doi:10.1212/wnl.45.6.1155
  • Hamed SA, Hamed EA, Kandil MR, et al. Serum thyroid hormone balance and lipid profile in patients with epilepsy. Epilepsy Res. 2005;66:173–183. doi:10.1016/j.eplepsyres.2005.08.004